Overview

The perspectives of healthcare providers (HCPs) on implementing CAB + RPV LA injection therapy have been extensively studied, with particular focus on its acceptability and feasibility in clinical practice. Early real-world experiences have shown that HCPs generally anticipate the initiation of CAB + RPV LA to be easy, and multiple benefits of administering the regimen to people with HIV (PWH) outweigh any potential barriers.

Key Findings

- **Introduction**: CAB + RPV LA is the first complete long-acting regimen for maintenance of viral suppression in currently viremic suppressed patients with HIV (PWH) and recommended by treatment guidelines.
- **Methods**: A prospective, observational, real-world study of utilization, clinical outcomes, experiences of HCPs and PWH initiating CAB + RPV LA across multiple US sites.
- **Results**: Sites Characteristics

### Conclusions

- **Clinic Changes Needed to Implement CAB + RPV LA**
  - In their current workflow, 50% of clinics (n=12/24) reported only needing to increase coordination with the clinic pharmacy (tied to their own pharmacy process) and/or add injection education (n=14/24 [58%]) to implement CAB + RPV LA; only 1 clinic reported needing in-staff skills.
  - Most clinics anticipated they could manage ongoing CAB + RPV LA treatments (n=19/24 [79%]) with the assistance of additional, most clinics administered (or plan to administer) treatments spread out over the course of a month (n=13/24 [54%])
- **Benefits of CAB + RPV LA**
  - The most frequently reported benefit of implementing CAB + RPV LA by HCPs included assurance of patient adherence (57%) and patient engagement in their HIV treatment (63%); Table.

### Table

<table>
<thead>
<tr>
<th>Clinical Change Needed to Implement CAB + RPV LA</th>
<th>Benefits of CAB + RPV LA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase or change in workflow to accommodate</td>
<td>- Assurance of patient</td>
</tr>
<tr>
<td>CAB + RPV LA treatments</td>
<td>adherence</td>
</tr>
<tr>
<td>Add injection education</td>
<td>- Patient engagement in</td>
</tr>
<tr>
<td>PWH treatment</td>
<td>HIV treatment</td>
</tr>
</tbody>
</table>

Acknowledgments: This study was funded by ViiV Healthcare. Editorial assistance and graphic design were provided under the direction of the editors by Aptaca, Inc. and Ultio graphics.


IDWeek 2022; October 19-23, 2022; Virtual and Washington, DC
This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific information requested and downloaded may relate to the use of our medicine(s) outside of their license.